Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good day! Today: A look at growing GLP-1 competition in China, a drug reviewed as part of the FDA’s shiny new fast-track voucher hits a roadblock, and Secretary Kennedy’s vaccine overhaul gets a hard look in federal court.
Also, psilocybin may be headed for approval despite mildly anticlimactic remission rates, and Ocular’s wet AMD drug does .… fine.Continue to STAT+ to read the full story…